AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22685032 — intervention group
Group type: COMPARATOR
Intervention: Active IBD (UC and CD)
Number of subjects: 133
Study 22685225 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary prevention treatment for children diagnosed with RHD
Number of subjects: 0
Study 22685225 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic evaluation
Number of subjects: 0
Study 22685225 — intervention group
Group type: COMPARATOR
Intervention: Cardiac auscultation
Number of subjects: 0
Study 22685225 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigation of risk factors associated with diagnosis and progression of RHD
Number of subjects: 0
Study 22687305 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab
Number of subjects: 81
Study 22688151 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 100
Study 22688151 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 100
Study 22688151 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 100
Study 22689675 — intervention group
Group type: EXPERIMENTAL
Intervention: Extramedullary disease presence
Number of subjects: 1965
Study 22691114 — intervention group
Group type: EXPERIMENTAL
Intervention: AG+AA genotype of SNP c.-238G>A of TNFα gene
Number of subjects: 942
Study 22691114 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriers positive for AG+AA genotype and A-allele of SNP c.-308G>A
Number of subjects: 942
Study 22691114 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants of TNFα
Number of subjects: 942
Study 22691124 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive glass (BioRestore™, Inion Oy, Tampere, Finland) used in socket ridge preservation procedure
Number of subjects: 13
Study 22691124 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive glass (BioRestore™, Inion Oy, Tampere, Finland)
Number of subjects: 13
Study 22692507 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Number of subjects: 559
Study 22693172 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Müllerian hormone (AMH) at a cut-off value of 20 pmol/l
Number of subjects: 262
Study 22693172 — intervention group
Group type: COMPARATOR
Intervention: Morphologic description (PCOM)
Number of subjects: 262
Study 22693229 — intervention group
Group type: EXPERIMENTAL
Intervention: Measles-mumps-rubella vaccination (MMR)
Number of subjects: 193
Study 22693229 — intervention group
Group type: EXPERIMENTAL
Intervention: Measles-mumps-rubella revaccination (MMR) 4-5 years later
Number of subjects: 193
Study 22693229 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial study vaccination with HIV load ≤400 copies/mL
Number of subjects: 193
Study 22693229 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 3 fever or fatigue
Number of subjects: 193
Study 22693347 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 6166
Study 22693347 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 6166
Study 22694756 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (n=22)
Number of subjects: 57
Study 22694756 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation (n=15)
Number of subjects: 57
Study 22694756 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuro Emotional Technique (n=20)
Number of subjects: 57
Study 22695105 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg vitamin D3 from fish oil capsules
Number of subjects: 55
Study 22695105 — intervention group
Group type: COMPARATOR
Intervention: Multivitamin tablets
Number of subjects: 55
Study 22695254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridaforolimus (50 mg intravenous once weekly)
Number of subjects: 38
Study 22695763 — intervention group
Group type: EXPERIMENTAL
Intervention: EnSite™ NavX™ system during biventricular (BiV) pacing
Number of subjects: 5
Study 22695763 — intervention group
Group type: COMPARATOR
Intervention: EnSite™ NavX™ system during right ventricle (RV) pacing
Number of subjects: 5
Study 22695763 — intervention group
Group type: COMPARATOR
Intervention: M-mode echocardiography (echo) for reference
Number of subjects: 5
Study 22695871 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-5 cups coffee/day
Number of subjects: 489706
Study 22695871 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥6 cups coffee/day
Number of subjects: 489706
Study 22695871 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥6 cups coffee/day (proximal tumors)
Number of subjects: 489706
Study 22695871 — intervention group
Group type: EXPERIMENTAL
Intervention: Predominantly decaffeinated coffee
Number of subjects: 489706
Study 22695871 — intervention group
Group type: COMPARATOR
Intervention: Tea
Number of subjects: 489706
Study 22696017 — intervention group
Group type: EXPERIMENTAL
Intervention: JE-VC (Ixiaro)
Number of subjects: 120
Study 22696017 — intervention group
Group type: EXPERIMENTAL
Intervention: JE-MB
Number of subjects: 120
Study 22696176 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg inhaled salbutamol
Number of subjects: 1831
Study 22696435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesteryl ester transfer protein-inhibition
Number of subjects: 0
Study 22696435 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 22698490 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D)
Number of subjects: 752
Study 22698532 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic valve calcium (AVC) present (n = 894, 13.4%)
Number of subjects: 6685
Study 22698649 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass eradication of H pylori infection (1-week clarithromycin-based triple therapy followed by 10-day levofloxacin-based triple therapy for treatment failures)
Number of subjects: 0
Study 22698649 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass eradication of H pylori infection
Number of subjects: 0
Study 22699291 — intervention group
Group type: EXPERIMENTAL
Intervention: South Asians (SAs)
Number of subjects: 6040
Study 22699662 — intervention group
Group type: EXPERIMENTAL
Intervention: New technologies evaluated by the PEARL Network
Number of subjects: 0
Study 22699662 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative effectiveness research conducted by the PEARL Network
Number of subjects: 0
Study 22699662 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary clinical studies participation
Number of subjects: 0
Study 22699662 — intervention group
Group type: EXPERIMENTAL
Intervention: Benchmarking as a form of continuous feedback
Number of subjects: 0
Study 22699662 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaboration with oral health care and pharmaceutical industries
Number of subjects: 0
Study 22699667 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cGVHD (defined by NIH scale >2 points)
Number of subjects: 187
Study 22699667 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable logistic regression model including albumin, mouth pain, and total complement
Number of subjects: 187
Study 22699693 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted physical activity program (123 sessions over one year)
Number of subjects: 0
Study 22699956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 22699956 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 85
Study 22700038 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (125 mg)
Number of subjects: 16
Study 22700038 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 16
Study 22700038 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 16
Study 22700038 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 16
Study 22700038 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 16
Study 22700038 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 16
Study 22700038 — intervention group
Group type: COMPARATOR
Intervention: Placebo-MDMA (125 mg)
Number of subjects: 16
Study 22700038 — intervention group
Group type: COMPARATOR
Intervention: Placebo-placebo
Number of subjects: 16
Study 22700038 — intervention group
Group type: COMPARATOR
Intervention: Pretreatment-placebo
Number of subjects: 16
Study 22700038 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment-MDMA
Number of subjects: 16
Study 22700780 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS)
Number of subjects: 362
Study 22700780 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of auscultation and LUS
Number of subjects: 362
Study 22700780 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up measurements
Number of subjects: 362
Study 22700836 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BoNT-A)
Number of subjects: 404
Study 22700841 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnoea (OSA) diagnosis through pre-operative polysomnography
Number of subjects: 82
Study 22700841 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative polysomnography
Number of subjects: 82
Study 22700841 — intervention group
Group type: EXPERIMENTAL
Intervention: Age- and sex-adjusted multivariate regression analysis
Number of subjects: 82
Study 22701330 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 15000
Study 22701330 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 15000
Study 22701542 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supervised exercise for two weeks
Number of subjects: 60
Study 22701615 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib (100 mg, 200 mg, or 300 mg daily) combined with cetuximab and irinotecan
Number of subjects: 27
Study 22701615 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib with cetuximab and irinotecan
Number of subjects: 27
Study 22704876 — intervention group
Group type: EXPERIMENTAL
Intervention: OPG levels ≥ 75th percentile
Number of subjects: 221
Study 22704876 — intervention group
Group type: EXPERIMENTAL
Intervention: OPG levels in the highest quartile
Number of subjects: 221
Study 22704876 — intervention group
Group type: EXPERIMENTAL
Intervention: OPG1 as a continuous variable
Number of subjects: 221
Study 22704876 — intervention group
Group type: EXPERIMENTAL
Intervention: OPG serum levels collected 24h after infarction
Number of subjects: 221
Study 22704876 — intervention group
Group type: EXPERIMENTAL
Intervention: High OPG levels
Number of subjects: 221
Study 22705432 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaemia prevalence assessment
Number of subjects: 1269
Study 22705432 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency assessment using Green and King's index
Number of subjects: 1269
Study 22705432 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophoresis on a subsample
Number of subjects: 1269
Study 22705432 — intervention group
Group type: EXPERIMENTAL
Intervention: Stunting and wasting assessment
Number of subjects: 1269
Study 22707516 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab, 5 mg/kg or 10 mg/kg every 2 weeks
Number of subjects: 43
Study 22708895 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lacosamide loading dose of 200 mg
Number of subjects: 100
Study 22708895 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lacosamide loading dose of 300 mg
Number of subjects: 100
Study 22708895 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lacosamide loading dose of 400 mg
Number of subjects: 100
Study 22708895 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 100
Study 22709460 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 220 mg once daily
Number of subjects: 8062
Study 22709460 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg once daily
Number of subjects: 8062
Study 22709460 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 8062
Study 22709460 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 8062
Study 22709460 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuraxial anaesthesia
Number of subjects: 8062
Study 22709460 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination anaesthesia (general + peripheral nerve block or neuraxial + peripheral nerve block)
Number of subjects: 8062
Study 22709477 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET) for 3 weeks in-hospital and continued at home for 12 weeks
Number of subjects: 21
Study 22709833 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (± statin) for up to 5 years
Number of subjects: 11388
Study 22710249 — intervention group
Group type: EXPERIMENTAL
Intervention: Waveguide-based optical biosensor for the detection of TB-specific biomarkers (LAM, ESAT6, Ag85)
Number of subjects: 0
Study 22713099 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol 30μg-drospirenone 3mg plus metformin 1700 mg daily for 6 months
Number of subjects: 25
Study 22714121 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine treatment for 16 weeks
Number of subjects: 0
Study 22715281 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 22716943 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 769
Study 22717465 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised, moderately intense aerobic and resistance exercise program for 10 weeks
Number of subjects: 17
Study 22717743 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV1-LPL(S447X) gene therapy (alipogene tiparvovec) administered at 3 × 10(11) gc kg(-1) for cohorts 1 (n=2) and 2 (n=4) and 1 × 10(12) gc kg(-1) for cohort 3 (n=8). Immunosuppressants were also given to cohorts 2 and 3 for 12 weeks.
Number of subjects: 14
Study 22717743 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV1-LPL(S447X) gene therapy (alipogene tiparvovec)
Number of subjects: 14
Study 22719020 — intervention group
Group type: EXPERIMENTAL
Intervention: STAT3 decoy oligonucleotide
Number of subjects: 0
Study 22719020 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 0
Study 22719020 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic STAT3 decoy
Number of subjects: 0
Study 22719806 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (25(OH)D)
Number of subjects: 45
Study 22719806 — intervention group
Group type: COMPARATOR
Intervention: African Americans (AAs)
Number of subjects: 45
Study 22719806 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for 25(OH)D
Number of subjects: 45
Study 22719881 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab monotherapy 10 mg/kg q14 d until intolerable toxicity or disease progression
Number of subjects: 35
Study 22719881 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab monotherapy
Number of subjects: 35
Study 22719933 — intervention group
Group type: EXPERIMENTAL
Intervention: qLAMP (quantitative Loop-mediated isothermal Amplification)
Number of subjects: 2986
Study 22719933 — intervention group
Group type: COMPARATOR
Intervention: Standard bacterial cultures
Number of subjects: 2986
Study 22719975 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-223, miR-15a, miR-16, miR-122, miR-193*, and miR-483-5p
Number of subjects: 214
Study 22719975 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined variables (sepsis stage, SOFA scores, APACHE II scores, miR-15a, miR-16, miR-193b*, and miR-483-5p)
Number of subjects: 214
Study 22719975 — intervention group
Group type: COMPARATOR
Intervention: APACHE II scores
Number of subjects: 214
Study 22719975 — intervention group
Group type: COMPARATOR
Intervention: SOFA scores
Number of subjects: 214
Study 22719975 — intervention group
Group type: COMPARATOR
Intervention: Procalcitonin levels
Number of subjects: 214
Study 22719975 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-193b*
Number of subjects: 214
Study 22719975 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined variables
Number of subjects: 214
Study 22721660 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary reactivity testing (CRT)
Number of subjects: 293
Study 22721944 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking distance (six-minute walking distance)
Number of subjects: 44
Study 22721944 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-free mass index (FFMI)
Number of subjects: 44
Study 22721944 — intervention group
Group type: EXPERIMENTAL
Intervention: PaCO2 levels
Number of subjects: 44
Study 22721944 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-ischemic reactive hyperemia (RH-PAT) measurement
Number of subjects: 44
Study 22721971 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin/IL-2 combination therapy
Number of subjects: 9
Study 22721971 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 therapy
Number of subjects: 9
Study 22722065 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonbothersome tinnitus group
Number of subjects: 18
Study 22722065 — intervention group
Group type: COMPARATOR
Intervention: Normal healthy nontinnitus control group
Number of subjects: 18
Study 22722717 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin-eluting beads (DEB) in transarterial chemoembolization (TACE), 100-300 μm beads loaded with ≤100 mg doxorubicin, up to four sessions within 6 months.
Number of subjects: 13
Study 22722717 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin-eluting beads (DEB) in transarterial chemoembolization (TACE)
Number of subjects: 13
Study 22722755 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunospot assay
Number of subjects: 25
Study 22722755 — intervention group
Group type: COMPARATOR
Intervention: Skin testing
Number of subjects: 25
Study 22722755 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunospot assay (within 2 years of drug reaction)
Number of subjects: 25
Study 22722778 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH gel (80 units subcutaneously twice weekly for 6 months)
Number of subjects: 15
Study 22722778 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH gel
Number of subjects: 15
Study 22723305 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular profiling using coronary angiography and intravascular ultrasound; assessed at baseline and 6 to 10 months later.
Number of subjects: 506
Study 22723305 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline large plaque burden and low endothelial shear stress as predictors.
Number of subjects: 506
Study 22723305 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of independent baseline predictors.
Number of subjects: 506
Study 22723326 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapies (AET; leuprolide, tamoxifen, aromatase inhibitors)
Number of subjects: 18
Study 22723326 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic activity in the insula and hypothalamus measured by rCMRglu
Number of subjects: 18
Study 22723326 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to AET
Number of subjects: 18
Study 22723326 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 genotype
Number of subjects: 18
Study 22723441 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin activation of fatty acid uptake
Number of subjects: 15
Study 22723441 — intervention group
Group type: COMPARATOR
Intervention: Suppression of adipose fatty acid release
Number of subjects: 15
Study 22723456 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR in patients with WMH Grade 0 to 1 (none to mild)
Number of subjects: 2009
Study 22723456 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR in patients with WMH Grade 2 (moderate)
Number of subjects: 2009
Study 22723456 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR in patients with WMH Grade 3 (severe)
Number of subjects: 2009
Study 22723456 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of WMH with age
Number of subjects: 2009
Study 22723456 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of WMH with hypertension
Number of subjects: 2009
Study 22723456 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of WMH with cardiovascular disease
Number of subjects: 2009
Study 22723456 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of WMH with overweight (BMI >25 kg/m(2))
Number of subjects: 2009
Study 22723456 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of WMH with current smoking
Number of subjects: 2009
Study 22723456 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of WMH with eGFR
Number of subjects: 2009
Study 22723456 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis of WMH severity
Number of subjects: 2009
Study 22723579 — intervention group
Group type: EXPERIMENTAL
Intervention: AHSCT
Number of subjects: 28
Study 22723579 — intervention group
Group type: EXPERIMENTAL
Intervention: AHSCT in non-DKA patients
Number of subjects: 28
Study 22723579 — intervention group
Group type: EXPERIMENTAL
Intervention: AHSCT in DKA patients
Number of subjects: 28
Study 22723579 — intervention group
Group type: EXPERIMENTAL
Intervention: AHSCT in non-DKA group
Number of subjects: 28
Study 22723579 — intervention group
Group type: EXPERIMENTAL
Intervention: AHSCT in DKA group
Number of subjects: 28
Study 22723585 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (isocaloric exchange for carbohydrate)
Number of subjects: 209
Study 22723585 — intervention group
Group type: COMPARATOR
Intervention: Control (carbohydrate)
Number of subjects: 209
Study 22726923 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise intervention
Number of subjects: 0
Study 22727048 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal-bolus therapy with insulin detemir / insulin aspart
Number of subjects: 0
Study 22727048 — intervention group
Group type: COMPARATOR
Intervention: Human NPH insulin / human regular insulin
Number of subjects: 0
Study 22727547 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary energy density of solid food
Number of subjects: 107
Study 22727547 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake (kcal/day)
Number of subjects: 107
Study 22727547 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival
Number of subjects: 107
Study 22727547 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic inflammation
Number of subjects: 107